
Joel Stanley
2
APPEARANCES
2
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
Sep 18, 2026
Can Nature's Complexity Make Better Medicines? The Botanical Drug Revolution | Joel Stanley - CEO, AJNA BioSciences
17:40
17:50

Joel StanleyGUEST
Um, the majority of our drugs are synthetic, um, or semi-synthetic, but some of them are isolated from a natural source.

Joel StanleyGUEST
You're not allowed to manipulate it through column chromatography and strip out molecules and pair them back together even.
10 MINS LATER
Beyond Compliance: AJNA BioSciences' Joel Stanley on Bringing Botanical Medicine Through the FDA Pathway
8:59
9:16
9:39
9:52
20:00

Otis JohnsonHOST
Um, can you talk a little bit about the minimum regulatory requirements and why you felt that was not enough, um, uh, for physicians to trust it and, um, and, and credibly prescribe it? Can, can you talk a little bit about that?

Joel StanleyGUEST
Well, you know, I think that, that it's important to name the industry and the, the regulatory standards that come with the industry that hemp and, and CBD-based hemp products, um, have really been forced into.

Joel StanleyGUEST
And the FDA not only handles drug approval and approval of medical devices, um, it also regulates, um, food and dietary supplements.

Joel StanleyGUEST
And the, the general rules for dietary supplements are the bar is, is, is quite low.
10 MINS LATER

Otis JohnsonHOST
So how can real world evidence and observational data help guide the clinical development of botanical therapies? And if there are any limits, um, I'd like to hear about some of that.
